UNIVERSITY OF FLORENCE - Genome-wide identification of genetic markers of oxaliplatin-induced per...

Employer
Università degli Studi di Firenze - Dipartimento di Medicina Sperimentale e Clinica
Location
Italy
Posted
October 10 2017
Position Type
Full Time
Organization Type
Academia

Oxaliplatino (OHP) combined with folinic acid/fluorouracil or capecitabine, constitutes the basis of standard adjuvant chemotherapy (CHT) in colorectal cancer (CRC) (stages II-III). Peripheral neuropathy (PN) is the main OHP dose limiting toxicity and it develops as a severe form in 30-40% of patients (pts) suggesting that individual characteristics may affect its onset. When cumulative chronic PN occurs in stage II-III pts, their quality of life is compromized. Genetic and physiopathological bases of its onset are unknown.This prospective study that will be performed in stage II-III CRC pts, treated with adjuvant CHT including OHP, aims at identifying markers indicative of clinically relevant (grade ≥2 NCI-CTCAE v4.03), chronic PN (duration ≥7 days), induced by OHP. Genetic markers will be identified by Genome Wide analysis in 350 CRC pts (identification cohort) and validated in a separate cohort of 150 CRC pts (validation cohort)



This job comes from a partnership with Science Magazine and Euraxess